GlassScriptPhysician profile
Amy Smith Howard
NPI 1245473016
$5,137.65
in general payments reported to CMS, 2019-2025
19 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,135 · 2022: $718 · 2023: $1,093 · 2024: $941 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,209 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,209.27 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $988.18 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $696.30 | 2021-2025 | Invega Sustenna, Spravato, Invega |
| Teva Pharmaceuticals USA, INC. | $638.50 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $552.58 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $482.55 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $313.58 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $306.39 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $244.83 | 2021-2025 | Trintellix |
| Alkermes, INC. | $226.83 | 2021-2024 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $147.59 | 2024-2025 | Cobenfy |
| Abbott Laboratories | $135.98 | 2024 | Cardiomems |
| Sunovion Pharmaceuticals INC. | $81.42 | 2021-2022 | |
| Eisai INC. | $66.85 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $63.72 | 2022-2024 | Quviviq |
| Lundbeck LLC | $49.99 | 2022-2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $42.16 | 2023-2024 | Brixadi |
| Corium, LLC | $41.65 | 2023 | Azstarys |
| Almatica Pharma LLC | $31.12 | 2023 | Loreev Xr |
| Janssen Biotech, INC. | $27.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.